STUDY OF THE EFFECTIVENESS OF TARGETED THERAPY IN METASTATIC RENAL CELL CARCINOMA PATIENTS


如何引用文章

全文:

详细

Objective. To study the relapse-free overall survival in metastatic renal cell carcinoma (mRCC) patients after the targeted therapy and to develop optimal approach to the treatment shedule. Material and methods. The research included 88 mRCC patients of mean age of 55.5 + 9.6 years, 63 (71.6%) men and 25 (28.4%) women. 42.0% patients had a favorable prognosis, 52.3% - intermediate one and 5.7% of the cases had poor prognosis. First line targeted therapy was carried out in 88 patients, the second line - in 26 patients, and the third line - in 7 patients. Results. The one or several lines of targeted therapy allowed to achieve 20 months of a median in survival without progression of the disease. Several lines of treatment increased a median of general survival up to 42 months in comparison with the patients who were involved in the one line of treatment (a median = 30 months), p = 0.001. Side effects of targeted therapy were reversible. In the first line targeted therapy the preference was given to sunitinib, in the second line - to sorafenib. Sorafenib had an advantage in case of not light-cellular forms of renal carcinoma. In cases with favorable prognosis factors, metastases into organ parenchyma, targeted therapy with bevacizumab was carried out.

作者简介

Galina Alekseeva

Vladivostok Clinic Hospital No 2

Email: algala@dns.vl.ru
MD, PhD, Urologist, Vladivostok Clinic Hospital No 2, Vladivostok, 690105, Russian Federation Vladivostok, 690105, Russian Federation

L. Gurina

Primorsky Regional Oncology Dispensary

Vladivostok, 690105, Russian Federation

M. Volkov

Primorsky Regional Oncology Dispensary

Vladivostok, 690105, Russian Federation

E. Evtuchenko

Primorsky Regional Oncology Dispensary

Vladivostok, 690105, Russian Federation

参考

  1. Coppin C., Porzsolt F., Awa A. et al. Immunotherapy for advanced renal cell cancer // Cochrane Database Syst. Rev. 2005; (1): CD001425.
  2. Negrier S., Escudier B., Lasset C. et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal cell carcinoma. Groupe Francais d’Immunotherapie. N. Engl. J. Med. 1988; 338(18): 1272-8.
  3. Алексеев Б.Я., Калпинский А.С., Нюшко К.М. и др. Определение факторов прогноза эффективности терапии бевацизумабом у больных метастатическим почечно-клеточным раком. Онкоурология. 2013; (3): 17-23.
  4. Escudier B., Eisen T., Sradler W.M. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 2007; 356: 124-34.
  5. Calvo E., Escudier B., Motzer R.J. Everolimus in metastatic renal cell carcinoma subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1study. Eur. J. Cancer. 2012; 48(3): 333-9.
  6. Goebel P., Матвеев В.Б., Широкорад В.И. Индивидуальный подход в выборе таргетной терапии - основа успеха при лечении пациентов с метастатическим раком почки. Медицинский форум. Онкология, гематология и радиология. 2011; (4): 56-64. http://umedp.ru/articles/individualnyy_podkhod_v_vybore_targetnoy_terapii_osnova_uspekha_pri_lechenii_patsientov_s_metastatich.html
  7. Алексеев Б.Я., Калпинский А.С., Нюшко К.М., Каприн А.Д. Акситиниб в последовательной таргетной терапии больных метастатическим раком почки. Онкоурология. 2014; (3): 83-90.
  8. Motzer R.J., Hutson T.E., Reeves J. et al. Randomized open-label phase III trial of pazopanib versus sunitinib in first-line treatment of patients with metastatic renal cell carcinoma (MRCC): Results of the COMPARZ trial. In: 2012 ESMO Congress. 2012: Abstract LBA8.
  9. Gupta K., Miller J.D., Li J.Z. et al. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC) in literature revive. Cancer Treat. Rev. 2008; 34: 193-205.
  10. Rini B.I., Escudier B., Tomczak P. et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011; 378: 1931-9.
  11. Носов Д.А., Ворошилова Е.А., Саяпина М.С. Современное представление об алгоритме лекарственного лечения и оптимальной последовательности использования таргетных препаратов. Онкоурология. 2014; (3): 12-21.
  12. Атлас по классификации стадий злокачественных опухолей (AJCC): Пер. с англ. А.Д. Каприн, А.Х. Трахтенберг. М.: Практическая медицина; 2014.
  13. Heng D.Y., Xie W., Regan M.M. et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population based study. Lancet Oncol. 2013; 14(2): 141-8.

版权所有 © Eco-Vector, 2017


 


##common.cookie##